Home

Overview

EQx Fund operates an evergreen Angel Fund focused on diversified early stage investments in extraordinary Founders

Emotional Quotient (EQ): the ability to understand, cooperate with and motivate others

  • Leadership and Passion is key
  • Opportunistic/Industry-Agnostic
  • Industry Disruptors/High growth opportunities

About Us

About Us

picture1-e1521667564729.jpg
Ziad H. Moukheiber serves as Managing Partner for the EQx Fund. He is the CEO of the renowkned Boston Harbor Angels organization, which has boasted a series of successful exits and is recognized as one of the top Angel Groups in the country. Ziad maintains an Angel portfolio of his own, concentrated in early stage technology and life science opportunities. Prior to his current roles, he founded and ran an IT consulting firm, Silversword, which was acquired by NSK Inc. in 2015.
Picture2
Jason Kraus serves as a partner in the EQx Fund, specializing in deal flow. He has experience in the venture arm of a private family office and as a member for the Boston Harbor Angels. Jason founded a startup advisory firm, Prepare 4 VC, to coach entrepreneurs through the fundraising process and create more powerful pitches. He is also a co-founder of commercial real estate and early stage investment firm Equity Venture Partners

Contact

 

Immusoft Corporation, a Seattle, Wash.-based cell therapy company, announced today that it has received a Phase II Small Business Innovation Research grant (SBIR) from the National Institute of General Medical Sciences, part of the National Institutes of Health (NIH). The grant, in the amount of just over $3.5 million, will enable Immusoft to further advance its modified B cell approach to treating disease.

“We appreciate the NIH’s support of our approach,” says Sean Ainsworth, Immusoft’s CEO and Chairman of the Board. “This SBIR grant will help us expand upon our cutting-edge work in MPS I and further explore modalities for delivering proteins across the blood-brain barrier.”

MPS I (Mucopolysaccharidosis type I) is a rare childhood genetic disease that affects the body’s ability to produce IDUA (alpha-L-iduronidase), which is an essential enzyme that helps to break down long-chain sugars inside cells. When the sugar chains cannot be broken down and disposed of, they accumulate in the cells and cause progressive damage. This accumulation can happen in the tissues, including the brain.

Full Story

Portfolio Company Immusoft Recieves $3.5M Grant

Boston-based cloud storage startup Wasabi Technologies, Inc secured $68 million in Series B financing last month, according to company database Crunchbase, leading the city’s funding headlines in September. The Sept. 12 Forestay Capital investment was just one of several successful funding rounds for Beantown-based companies last month.

Read Full Story

Portfolio Company Wasabi Press Release